Days after gaining its first emergency use authorization from Indonesia, the business submitted to the health agency all modules required for the evaluation of NVX-CoV2373, its protein-based COVID-19 vaccine. In addition, the business expects regulators in countries such as India and the Philippines to make decisions on its vaccine in the coming weeks.
If the WHO gives its approval, Novavax will be able to start distributing doses to the COVAX programme, which provides vaccines to low-income countries. Novavax is ready to ship its vaccine all around the world, according to Stanley Erck, CEO and Director-Novavax. During a call Erck mentioned that Novavax’s partner, Serum Institute of India, has already created “tens of millions” of doses that are ready to export.
According to the corporation, it is on pace to petition for US approval by the end of the year. It also plans to give booster doses to high- and low-income countries around the world, as well as file a regulatory application for its children’s vaccines in the first quarter of 2021.
The vaccine producer from Maryland reported a larger third-quarter net loss of $322.4 million, or $4.31 per share, compared to $197.3 million a year ago. Increased development operations connected to its COVID-19 vaccine, including services provided under the US government agreement and royalties from licencing pacts, boosted revenue to $178.8 million.